The University of Newcastle researcher who led a cannabis-based cancer study has lost his case before the Fair Work Commission and been terminated for research misconduct, following revelations that women's cells were used in mice experiments without patient consent. The research centre he directed has been shut down, all samples and data destroyed, staff lost their jobs, PhD students abandoned their studies, and the university has had to repay donors.
Fair Work Commission documents have revealed the termination of the University of Newcastle researcher who led a high-profile study into cannabis extracts as a potential cancer treatment. The research, announced in 2021 as "groundbreaking" by the university and ASX-listed hemp grower Ecofibre, claimed to show cancerous cells being "completely eradicated" by a cannabis extract. Ecofibre stated at the time that "all patients have responded positively," although the experiments were conducted on patient samples, not on patients themselves. Patents had been filed.
Almost five years later, the picture is starkly different. The researcher has been sacked for research misconduct after an investigation found that women's cells were used in mice experiments without the patients' consent. The research centre he directed has closed, with all samples and data from the suspect research destroyed. Staff have lost their jobs, and PhD students have had to abandon their studies. The university has had to repay donors.
Ecofibre, which sells cannabis-based treatments including "Endo Relief Cream" and cannabinoid vaginal suppositories, had partnered with the university for the research. The company's 2021 announcement had trumpeted the results as poised to transform women's health. The Fair Work Commission outcome effectively upholds the university's decision to terminate the researcher for misconduct.
Analysis
Why This Matters
- The case raises serious questions about patient consent and ethical oversight in university-industry research partnerships.
- It has resulted in destroyed data, lost jobs, abandoned PhD projects, and the closure of a research centre, representing a significant institutional failure.
- The scandal may erode public trust in medical research and in the oversight mechanisms meant to protect patients and their biological samples.
Background
The research was a collaboration between the University of Newcastle and Ecofibre, a hemp grower listed on the ASX. In 2021, the partners announced promising results from experiments where a cannabis extract appeared to eradicate cancer cells under a microscope. Patents were filed and the work was touted as a potential breakthrough in women's health. However, an investigation later revealed that the cells used in the experiments had been taken from women without their informed consent, leading to findings of research misconduct.
Key Perspectives
The University of Newcastle: The university terminated the researcher, shut the research centre, destroyed all suspect samples and data, and repaid donors, indicating it regards the misconduct as severe and has taken steps to contain the damage.
Ecofibre: The company had publicly promoted the research as groundbreaking. It has not commented publicly on the findings, but the commercial products linked to the research may face reputational risk.
Patients and donors: The women whose cells were used without consent have had their rights violated. Donors who gave money relying on the integrity of the research have been repaid, but the broader harm to trust remains.
Academic community: The case highlights weaknesses in university oversight of research ethics, particularly when commercial pressures are involved, and may prompt calls for tighter regulation.
What to Watch
- Any further legal action from affected patients or from the researcher, who may pursue other avenues.
- Whether the National Health and Medical Research Council or other regulators investigate the university's ethics processes.
- The impact on Ecofibre's business and its relationship with research institutions.
- Reforms at the University of Newcastle to strengthen patient consent procedures and research governance.